



Advancing Transfusion and
Cellular Therapies Worldwide

AABB SUMMARY: DONATION OF CCP AND BLOOD COMPONENTS FOLLOWING COVID-19 VACCINES OR CCP TRANSFUSION - Updated 01 07 2021

DONOR DEFERRALS:

1-Blood donor deferral following COVID-19 vaccines is not required. Consider the following:

- FDA does *not* have a policy requiring deferral of *routine* blood donors following COVID-19 vaccination.
- In response to questions from AABB, FDA:
 - Confirmed that it would be reasonable to have no donor deferral following mRNA COVID-19 vaccines.
 - Offered that a 14-day deferral is reasonable following a live-attenuated vaccine (we are expecting very few of those).
- Any decision to update policies for deferral following COVID vaccines is left to the discretion of the Medical Director.
- For more information from AABB Standards and FDA – refer to the **Resources Section below.**

2-Donation following CCP transfusion requires deferral.

- CCP donors must meet all allogeneic blood donor criteria and deferral requirements, including the 3-month deferral from the date of CCP transfusion.

3-Individuals receiving COVID-19 vaccines are not eligible to donate CCP – [FDA's Nov 2020 CCP EUA guidance](#) (bottom of page 6) **FDA states:**

Note: You should not collect COVID-19 convalescent plasma from individuals who have received an investigational COVID-19 vaccine because of the uncertainty regarding the quality of the immune response produced by such investigational vaccines.

- FDA also shared information during the AABB Annual Meeting Session, [Live with FDA on the CCP Regulatory Landscape](#) - refer to slide 29 for CCP donation after vaccination and slides 27-28 for blood donation.

4-Recovered COVID-19 patients who are eligible to donate CCP and also receive a COVID-19 vaccine after recovery – **Please check back**

Update coming soon based on the Jan 7 AABB Hot Topic session with FDA's Peter Marks. AABB is verifying our understanding of this new information to ensure the accuracy of our revisions.

5-FDA confirmed that deferral following receipt of monoclonal antibodies is at the discretion of the physician oversight.

RESOURCES:

- Aug 7th [REGULATORY UPDATE: Investigational Vaccines and Deferral for Donors of Blood and Convalescent Plasma](#)
- Nov 20th [REGULATORY UPDATE: Evaluating Donor Risk and Deferrals Following Vaccination](#)
- Oct 5th [Live with FDA on the CCP Regulatory Landscape](#) AABB Annual Meeting
- **AABB Standards** – Sept 2020 [Guidance for the Standards for Blood Banks and Transfusion Services, 32nd edition](#) - Deferral following COVID-19 vaccines